Skip to content
Home/Companies/Biotech/Immutrin
IM

Immutrin

Biotech·UK·Active·1yr hold

Immutrin is a biotech company, headquartered in UK.

Entry
2025
Hold
1yr
Status
Active
Est. EV
–

Who owns Immutrin?

Immutrin is currently owned by Cambridge Innovation Capital through CIC Fund II (2022 vintage), since 2025.

Hand-verified · updated 2026-07-08

Cambridge Innovation Capital
Investor
Cambridge Innovation Capital
CIC Fund II · 2022 · VC

Key facts

HQUK
SectorBiotech
StatusActive

More from CIC Fund II

Other portfolio companies in the same fund.

TRIMTECH Therapeutics
Active
BiotechUK· 2025
Forefront RF
Active
TelecomUK· 2024
Nuclera
Active
BiotechUnited Kingdom· 2024
Complement Therapeutics
Active
BiotechUK· 2023
Mosaic TX
Active
BiotechUK· 2023
T-Therapeutics
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings